IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings

IRVINE, CA / ACCESSWIRE / November 3, 2022 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2023 first quarter ended September 30, 2022. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2023 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2022 increased $1.1 million, or 11%, to $11.1 million from $10.0 million for the three months ended September 30, 2021. The increase is driven primarily by $0.8 million in increased repairs of the surgical handpiece we sell to our largest customer as well as increases of $0.7 million in sales of our NRE & proto-type offerings. Offs

IRVINE, CA / ACCESSWIRE / August 25, 2022 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2022 fourth quarter and full-year ended June 30, 2022.Quarter Ended June 30, 2022Net sales for the three months ended June 30, 2022 increased $3.2 million, or34%, to $12.6 million from $9.4 million for the three months ended June 30, 2021, due primarily to increased medical device sales and repair revenue. Grossprofit for the threemonths ended June 30, 2022 increased $0.3 million, or 10%, to $3.4 million from $3.1 million for the same period in 2021. Although gross profit increased, our gross margin fell from 33% for the three months ended June 30, 2021 to 27% for the th

IRVINE, CA / ACCESSWIRE / August 26, 2021 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2021 fourth quarter and full-year ended June 30, 2021.Quarter Ended June 30, 2021Net sales for the three months ended June 30, 2021 decreased $1.7 million, or15%, to $9.4 million from $11.1 million for the three months ended June 30, 2020, due primarily to decreased medical device sales. This is due to two product launches in the prior fiscal year which had high initial sales volumes, which is typical, as our customers generally order in higher volumes in the beginning of a product introduction. Also, six to twelve months following launch our customers typically begin re

Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.35 by 45.71 percent. This is a 47.22 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $14.29 million which beat the analyst consensus estimate of $13.20 million by 8.28 percent. This is a 9.28 percent increase over sales of $13.08 million the same period last year.

Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.35 by 60 percent. This is a 41.67 percent decrease over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $12.59 million which beat the analyst consensus estimate of $11.50 million by 9.46 percent. This is a 11.58 percent increase over sales of $11.28 million the same period last year.

Gainers Xilio Therapeutics (NASDAQ:XLO) shares rose 10.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $18.2 million. Sensus Healthcare (NASDAQ:SRTS) stock increased by 9.58% to $4.0. The company's market cap stands at $65.5 million. The company's, Q4 earnings came out today. Corvus Pharma (NASDAQ:CRVS) stock moved upwards by 8.49% to $2.17. The market value of their outstanding shares is at $106.4 million. SenesTech (NASDAQ:SNES) shares moved upwards by 6.86% to $1.09. Coeptis Therapeutics (NASDAQ:COEP) stock rose 6.2% to $0.51. The company's market cap stands at $17.3 million. Bright Green (NASDAQ:BGXX) shares moved upwards by 4.

Pro-Dex (NASDAQ:PDEX) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.32 by 153.13 percent. This is a 158.62 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $11.94 million which beat the analyst consensus estimate of $11.20 million by 6.59 percent. This is a 7.68 percent increase over sales of $11.09 million the same period last year.

Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.33 by 27.27 percent. This is a 10.53 percent increase over earnings of $0.38 per share from the same period last year.

Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.26 by 38.46 percent. This is a 200 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $13.08 million which beat the analyst consensus estimate of $9.80 million by 33.46 percent. This is a 41.17 percent increase over sales of $9.27 million the same period last year.

According to Benzinga Pro data Pro-Dex (NASDAQ:PDEX) posted a 18.31% decrease in earnings from Q1. Sales, however, increased by 1.76% over the previous quarter to $11.28 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Pro-Dex is not utilizing their capital as effectively as possible. In Q1, Pro-Dex earned $1.08 million and total sales reached $11.09 million. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher

Pro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.29 by 17.24 percent. This is a 4 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $11.28 million which beat the analyst consensus estimate of $10.40 million by 8.48 percent. This is a 10.90 percent increase over sales of $10.17 million the same period last year.

Pulled from Benzinga Pro data, Pro-Dex (NASDAQ:PDEX) posted Q1 earnings of $1.08 million, an increase from Q4 of 23.42%. Sales dropped to $11.09 million, a 12.11% decrease between quarters. In Q4, Pro-Dex earned $1.41 million, and total sales reached $12.62 million. Why Is ROIC Significant? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q1, Pro-Dex posted an ROIC of 2.52%. Keep in min

SC 13D - PRO DEX INC (0000788920) (Filed by)

SC 13D/A - PRO DEX INC (0000788920) (Subject)

IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended March 31, 2024Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023, due primarily to an increase in medical device product revenue of $2.8 million offset by a decrease in non-recurring engineering and repair revenue of $736,000 and $635,000 respectively.Gross profit for

IRVINE, CA / ACCESSWIRE / February 8, 2024 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2024 second quarter ended December 31, 2023. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended December 31, 2023Net sales for the three months ended December 31, 2023, increased $1.3 million, or 12%, to $12.6 million from $11.3 million for the three months ended December 31, 2022, due primarily to an increase in repair revenue related to the orthopedic surgical handpiece that we sell to our largest customer. As previously disclosed, we began an enhanced repa

IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings

PHOENIX, AZ / ACCESSWIRE / October 26, 2023 / The Stock Day Podcast welcomed Pro-Dex, Inc. (NASDAQ:PDEX)("the Company"), a company that specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets.Dunehoo began the interview by asking about the Company's 4th quarter and full-year financial results. "Our topline sales were 10% greater than the year before, which reflected a good year-over-year performance," shared Van Kirk. "We also announced in our press release that our new building is now fully operational, which we have been looki

IRVINE, CA / ACCESSWIRE / October 13, 2023 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2023 fourth quarter and full-year ended June 30, 2023. The Company also filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023, with the Securities and Exchange Commission ("SEC") today.Quarter Ended June 30, 2023Net sales for the three months ended June 30, 2023 decreased $2.0 million, or16%, to $10.6 million from $12.6 million for the three months ended June 30, 2022, due primarily to decreased medical device sales offset by increased repair revenue. We do not have much visibility into our customers' distribution networks, but we surmise the dec

IRVINE, CA / ACCESSWIRE / May 4, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2023 third quarter ended March 31, 2023. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2023 with the Securities and Exchange Commission today.Quarter Ended March 31, 2023Net sales for the three months ended March 31, 2023, increased $3.8 million, or 41%, to $13.1 million from $9.3 million for the three months ended March 31, 2022, due primarily to increased repair revenue of $3.2 million related to an enhanced repair program launched this fiscal year to upgrade the handpiece we sell our largest customer to its most current genera

Phoenix, Arizona--(Newsfile Corp. - February 14, 2023) - The Stock Day Podcast welcomed Pro-Dex, Inc. (NASDAQ:PDEX) ("the Company"), a company that specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. CEO of the Company, Rick Van Kirk, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company's second quarter results, which were recently made public. "We are pleased with the quarter, particularly our topline," said Van Kirk. "I think it is reflecting our overall growth, and we are still trend

IRVINE, CA / ACCESSWIRE / February 2, 2023 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2023 second quarter ended December 31, 2022. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2023 with the Securities and Exchange Commission today.Quarter Ended December 31, 2022Net sales for the three months ended December 31, 2022 increased $1.1 million, or 11%, to $11.3 million from $10.2 million for the three months ended December 31, 2021, due primarily to sales of the orthopedic surgical handpiece that we sell to our largest customer coupled with increased repair revenue of that same handpiece.Gross profit for the th

8-K - PRO DEX INC (0000788920) (Filer)

10-Q - PRO DEX INC (0000788920) (Filer)

8-K - PRO DEX INC (0000788920) (Filer)

DEFA14A - PRO DEX INC (0000788920) (Filer)

DEF 14A - PRO DEX INC (0000788920) (Filer)

8-K - PRO DEX INC (0000788920) (Filer)

10-K - PRO DEX INC (0000788920) (Filer)

8-K - PRO DEX INC (0000788920) (Filer)

8-K - PRO DEX INC (0000788920) (Filer)

SD - PRO DEX INC (0000788920) (Filer)